Finally, a systematic review and meta-analysis on efficacy of roxadustat for anemia in patients with NDD-CKD revealed that roxadustat significantly increased the Hb response rate compared with placebo in the NDD-CKD group (Liu et al., 2021; Tang et al., 2021). Here, GSTM1 is linked to chronic kidney disease.